Jubilant Pharmova Ltd - 530019 - Investor Meet
Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be attending Group Meeting on May 30, 2023. We enclose details of the Investors/ Analysts for the same. The schedule may undergo change due to exigencies on the part of Investors/ Analysts/ Company. Jubilant Pharmova Ltd - 530019 - Related Party Transactions - H2 FY 23
Related Party Transactions - H2 FY 23 Jubilant Pharmova Ltd - 530019 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to the SEBI Circular no. CIR/CFD/CMD1/27/2019 dated February 8, 2019, titled Annual Secretarial Compliance Report dated May 29, 2023 for the financial year 2022-23. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herewith Investor Presentation on the financials and performance of the Company for the Financial Year ended March 31, 2023. Jubilant Pharmova Ltd - 530019 - Board Meeting Outcome for Dividend Declaration
Dividend Declaration Jubilant Pharmova Ltd - 530019 - Audited Results For The Quarter And Year Ended March 2023
Audited Results for the quarter and year ended March 2023 Jubilant Pharmova Ltd - 530019 - Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of Audited Financial Results For FY Ending March 2023 And Recommendation Of Dividend.
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 ,inter alia, to consider and approve Jubilant Pharmova Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023,inter alia, to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2023; and Recommendation of Dividend for the Financial Year ended March 31, 2023. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR) - Newspaper Publication